PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a late-stage trial. Read more here.

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer made one thing clear this week: It's officially back in the obesity race.